Venture lending is seen as offering higher returns for higher risk. So why, against such a volatile backdrop, is fundraising surging ahead?
The Silicon Valley veteran talks about his investment in Rigetti and why he says there is a lot of excitement regarding the nascent field of quantum computing.
After a record year in 2019, investors remain bullish on the region and say the momentum will continue far past 2020's uncertainties.
Tom Walker of Rev1 Ventures addresses the question of whether investors should back biotech start-ups that focus on the coronavirus and other potential pandemics. Here's what you should know.
Appetite for biopharma is on the rise as investors want to back scientific advances and the recession-proof sector, and generalist VCs don’t want to miss out on potential outsized returns.
The online provider of personal healthcare will likely not be doing a reverse merger with a SPAC soon, according to a venture source.
As more venture firms become accustomed to virtual pitches, they’re emphasizing reference checks and setting up multiple Zoom calls as a way to verify their investments and better get to know the founders.
VC is not entirely insulated from the impact of the pandemic and economic slowdown, but it sure feels like it really is business as usual.
Q2 funding rebounded due to a handful of megarounds while the sector saw its first IPO and a potential shift in focus.
We all are aware of how covid-19 is impacting our lives. But I wonder how due diligence and the art of picking deals will be affected long-term.

Copyright PEI Media

Not for publication, email or dissemination